ALX Oncology (ALXO)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Oncologysrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Dilution Risk
MEDIUM DILUTION RISKDilution score: 40/100 (MEDIUM), 15.2 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 5.3% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- ALX Oncology Announces Nature Medicine Publication of ASPEN-06 Phase 2 Clinical Data Demonstrating Strong Responses and Durable Clinical Benefit with Evorpacept in HER2-Positive Gastric Cancer
- ALX Oncology to Present at Upcoming Investor Conferences in September
- Is ALX Oncology Holdings (ALXO) Stock Outpacing Its Medical Peers This Year?
- ALX Oncology Reports Second Quarter 2026 Financial Results and Provides Corporate Update
- ALX Oncology Appoints Scott Garland as Chairman of the Board and Michael Listgarten as General Counsel
- ALX Oncology Targets Key Readouts to Advance CD47, EGFR Cancer Drug Programs
- ALX Oncology (ALXO) Q1 2026 Earnings Transcript
- ALX Oncology’s Evorpacept in Combination with Zanidatamab Generates Promising, Durable Response in Patients with Advanced HER2-Positive Breast Cancer and High CD47 Expression
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Recent Publications
- Decentralised oncology trials: decentralisation as a tool, not the goal. — BMJ Oncol 2026 PMID 42781060
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for ALX Oncology.
Full ALXO Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.